Elie G. Dib: Key considerations for ...

Dr. Elie G. Dib

Claim this profile

Genesys Hurley Cancer Institute

Expert in Skin Cancer
Studies Multiple Myeloma
38 reported clinical trials
105 drugs studied

Area of expertise

1Skin Cancer
Global Leader
Elie G. Dib has run 11 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
EGFR negative
2Multiple Myeloma
Elie G. Dib has run 6 trials for Multiple Myeloma. Some of their research focus areas include:
Stage I
Stage II
Stage III

Affiliated Hospitals

Image of trial facility.
Genesys Hurley Cancer Institute
Image of trial facility.
Saint Joseph Mercy Hospital

Clinical Trials Elie G. Dib is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria

More about Elie G. Dib

Clinical Trial Related6 years of experience running clinical trials · Led 38 trials as a Principal Investigator · 20 Active Clinical Trials
Treatments Elie G. Dib has experience with
  • Nivolumab
  • Lenalidomide
  • Dexamethasone
  • Atezolizumab
  • Durvalumab
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Elie G. Dib specialize in?
Is Elie G. Dib currently recruiting for clinical trials?
Are there any treatments that Elie G. Dib has studied deeply?
What is the best way to schedule an appointment with Elie G. Dib?
What is the office address of Elie G. Dib?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security